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ABSTRACT
We evaluated high-affinity receptor for IgE (Fce RI)-
binding serum IgE in patients with atopic kerato-
conjunctivitis (AKC; n = 31) and with seasonal allergic
conjunctivitis (SAC; n = 13) by enzyme-linked immuno-
sorbent assay (ELISA) using a recombinant soluble
form of the human Fc e RIa ectodomain (soluble a ). The
quantities of Fce RI-binding IgE are compared with
those of total IgE measured by a conventional sand-
wich ELISA. Both of the quantities of Fce RI-binding and
total IgE in AKC were significantly larger than those in
SAC (P < 0.001). In contrast, the proportion of Fce RI-
binding IgE (Fce RI-binding IgE/total IgE; %) in SAC was
significantly larger than that in AKC (P < 0.001),
although significant reverse correlation was observed
between the proportion of Fce RI-binding IgE and total
IgE in both AKC and SAC. Significantly, a higher 
proportion of Fce RI-binding IgE in SAC than that in
AKC may reflect the differences in pathologic states of
AKC and SAC that are caused by a disparity in immune
responses in these diseases.
Key words: atopic keratoconjunctivitis, ELISA, Fce RI,
Fce RI-binding IgE, seasonal allergic conjunctivitis.
INTRODUCTION
The high-affinity receptor for IgE, Fce RI, is expressed on
mast cells and basophils. Cross-linking of IgE on the
receptors by multivalent antigens activates these cells and
induces cellular degranulation, resulting in allergic
inflammation. In patients with allergic diseases, serum
IgE values are generally increased compared with those
in normal subjects. Among all IgE molecules in the
serum, IgE that actually induce an allergic reaction
should be able to bind to the receptor. Therefore, it is of
great importance to estimate the quantities of serum IgE
actually able to bind to Fce RI to evaluate clinical condi-
tions of patients with allergic diseases.
Fce RI has a tetrameric structure composed of a -, b -
and g 2-chains, of which the a -chain binds IgE with high
affinity.1–3 Recently, Ra and colleagues developed a novel
enzyme-linked immunosorbent assay (ELISA) system to
detect Fce RI-binding IgE by using a recombinant soluble
form of the human Fce RIa ectodomain (soluble a ).4 In the
present study, we measured serum Fce RI-binding IgE in
patients with atopic keratoconjunctivitis and seasonal
conjunctivitis by this newly developed ELISA (soluble-a
ELISA) and compared the quantities of Fce RI-binding IgE




Sera were obtained from 31 patients with atopic kerato-
conjunctivitis (AKC; 15 men and 16 women; mean ±SD,
21.4 ± 6.3 years old) and 13 patients with seasonal
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allergic conjunctivitis (SAC; 6 men and 7 women;
39.8 ± 17.3 years old). The study followed the tenets of
the Declaration of Helsinki.
Enzyme-linked immunosorbent assay to
detect Fce RI-binding IgE using soluble a
Microtiter® Plates (Immulon 2; Dynatech Laboratories,
Chantilly, VA, USA) were coated with 180 ng soluble a
produced by CHO transfectants4–6 in 90 m L 50 mmol/L
carbonate buffer (pH 9.4) overnight at 4°C. Each well
was washed five times with phosphate-buffered saline
(PBS), pH 7.2, containing 0.05% Tween 20 (Wako Pure
Chemical Industries Ltd, Osaka, Japan; washing buffer),
filled with 200 m L PBS containing 1% casein (skimmed
milk; Snow-Brand Industries Co. Ltd, Sapporo, Japan)
and 0.02% NaN3 and incubated for 1 h at 37°C. Plates
were washed and 100 m L human IgE, purified from the
serum of an IgE myeloma patient, or sera diluted with PBS
containing 0.1% casein was added to each well and the
plates were incubated for 3 h at 37°C. Each well was
washed, filled with 100 mL horseradish peroxidase
(HRP)-labeled goat antihuman IgE (Organon Teknica
Corp., Durham, NC, USA) (2.32 m g/mL in PBS contain-
ing 0.1% casein) and plates were incubated for 1 h at
37°C. After washing, 100 m L o-phenylenediamine (OPD;
Wako Pure Chemical Industries Ltd; 2 mg/mL in citrate
phosphate buffer pH 5.0, containing 0.015% H2O2) was
added to each well and the plates were incubated at
room temperature in the dark for 15 min. The enzyme
reaction was stopped by adding 100 m L 2 mol/L H2SO4
to each well. Optical absorbance at 490 nm was read
using Bio-Rad® microplate reader (model 450; 
Bio-Rad Laboratories Inc., Hercules, CA, USA).
Enzyme-linked immunosorbent assay to
detect total IgE by the sandwich method 
To evaluate total IgE, ELSIA®-IgE kits (International
Reagents Corp., Kobe, Japan) were adopted. The plates
were coated with a monoclonal mouse antihuman IgE
antibody, filled with standard IgE or diluted sera, incu-
bated for 1 h at room temperature and washed five times
with washing solution. Peroxidase (POD)-labeled goat
antihuman IgE antibody was added to each well and the
plates were incubated for 30 min at room temperature,
washed and then incubated with OPD in substrate solu-
tion for 30 min in the dark at room temperature. The
reaction was stopped by adding 2 mol/L H2SO4 to each
well and the optical absorbance was read as described
earlier.
Statistical analysis
Data were statistically analyzed by the Mann–Whitney 
U-test and Fisher’s Z-transformation using STATV IEW ®
(Abacus Concepts, Inc., Berkeley, CA, USA). A probabil-
ity of 5% or less was considered statistically significant.
RESULTS
Comparison of Fce RI-binding and total IgE
levels in the sera of AKC and SAC patients
The values of Fce RI-binding serum IgE detected by the
newly developed soluble-a ELISA were compared with
those of total IgE detected by a conventional sandwich
ELISA (Table 1). The values of Fce RI-binding IgE were 
substantially lower than those of total IgE in both AKC and
SAC sera, suggesting that all of the serum IgE could not
necessarily bind to the Fce RI. The quantity of Fce RI-binding
IgE in AKC patients (563 ± 341 ng/mL) was significantly
larger than that in SAC (222 ± 232 ng/mL, P < 0.001). 
A significant difference was also observed between the
quantity of total IgE in AKC (4685 ± 6739 ng/mL) and
that in SAC (418 ± 570 ng/mL, P < 0.0001). In remark-
able contrast, the proportion of Fce RI-binding IgE was
significantly larger in SAC (73.3 ± 24.7%) than in AKC
(31.9 ± 24.3%, P < 0.0001), as shown in Fig. 1. When
we plotted the Fce RI-binding IgE against total IgE (Fig. 2), a
correlation was observed between these values in both
AKC (r = 0.770, P < 0.0001) and SAC (r = 0.950,
P < 0.0001).
The proportion of Fce RI-binding IgE in AKC
and SAC sera
A reverse correlation was observed in the plot of Fce RI-
binding IgE/total IgE (%) against total IgE (ng/mL) in both
AKC (r = – 0.588, P < 0.0005) and SAC (r = – 0.741,
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Table 1 Comparison of Fce RI-binding and total IgE levels in
the sera of AKC and SAC patients
Data are expressed as the mean ± SD. *P < 0.0001, †P < 0.001
compared with seasonal allergic conjunctivitis (SAC) patients. AKC,
atopic keratoconjunctivitis.
AKC SAC
Total IgE (ng/mL) 4685 ± 6739* 418 ± 570
Fce RI-binding IgE (ng/mL) 563 ± 341† 222 ± 232
Fce RI-binding IgE/total IgE (%) 31.9 ± 24.3* 73.7 ± 24.7
P < 0.005), as shown in Fig. 3. Particularly in hyper-IgE
sera (IgE > 5000 ng/mL) from AKC patients, the propor-
tion of Fce RI-binding IgE was below 20%.
DISCUSSION
It is well known that IgE plays a crucial role in allergic
reactions by activating mast cells and basophils to
release a variety of inflammatory mediators and cyto-
kines. When Fce RI-bound IgE on mast cells are
cross-linked with multivalent antigens, a series of bio-
chemical cascades are triggered toward cellular
activation. In addition, there have been several papers
recently published on the expression and function of
Fce RI in other kinds of cells. Langerhans cells in the
skin,7–9 some populations of eosinophils10,11 and mono-
cytes12 also express Fce RI on the cell surface and are
activated by cross-linking of Fce RI. Therefore, it is impor-
tant to evaluate functional IgE that actually binds to Fce RI
for a further insight into allergic states.
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Fig. 1 Comparison of the proportion of Fce RI-binding serum
IgE in atopic keratoconjunctivitis (AKC) and seasonal allergic
conjunctivitis (SAC). Serum IgE that bound to the recombinant
soluble human Fce RIa ectodomain, coated on the plates, was
detected by a polyclonal antihuman IgE antibody (Fce RI-
binding IgE). Serum total IgE was evaluated by a conventional
sandwich enzyme-linked immunosorbent assay. The proportion
of Fce RI-binding IgE in SAC (73.7 ± 24.7%) was significantly
larger than that in AKC (31.9 ± 24.3%). *P < 0.0001, (–),
mean.
Fig. 2 Correlation between the quantities of Fce RI-binding
and total IgE. A positive correlation was observed both 
in atopic keratoconjunctivitis (s; n = 31, r = 0.770,
P < 0.0001, y = 0.039x + 380.7) and in seasonal allergic
conjunctivitis (d; n = 13, r = 0.950, P < 0.0001,
y = 0.38x + 60.5).
Fig. 3 Correlation between the quantity of total IgE and the
proportion of Fce RI-binding IgE. A negative correlation was
observed both in atopic keratoconjunctivitis (s; n = 31,
r = – 0.588, P < 0.0005; y = – 0.0021x + 41.9) and in
seasonal allergic conjunctivitis (d; n = 13, r = – 0.741,
P < 0.005, y = – 0.032x + 86.6).
Soon after the discovery of IgE, Ishizaka and Ishizaka
reported that the quantity of cell-binding IgE did not nec-
essarily correlate with total serum IgE levels in atopic
individuals.13 Subsequently, there were several reports
published that suggested that serum IgE may be hetero-
geneous with regards to cell-binding and histamine-
releasing properties in the passive cutaneous anaphylaxis
(PCA) reaction.14–17 Although a variety of ELISA systems
are widely adopted to evaluate serum IgE levels, as one
of the useful means for clinical diagnosis of allergy, they
are not concerned with the ability of IgE to bind to the
receptor.
We have developed a novel ELISA system to detect
Fce RI-binding IgE (soluble-a ELISA) and have evaluated
Fce RI-binding serum IgE in patients with AKC and SAC.
The quantity of Fce RI-binding serum IgE correlated with
the serum total IgE level, both in AKC and SAC (Fig. 2). In
a remarkable contrast, when we plotted the proportion of
Fce RI-binding IgE against total IgE, a reverse correlation
was observed in both of the two groups (Fig. 3) as
observed in patients with atopic dermatitis, bronchial
asthma and in normal controls.4 Particularly in hyper-IgE
sera from AKC patients (> 5000 ng/mL), the proportion
of Fce RI-binding IgE was less than 20% (Fig. 3) and there
was a significant difference in this value between the two
groups (Fig. 1). Atopic keratoconjunctivitis is a chronic
keratoconjunctivitis often observed with atopic dermatitis
and SAC is an acute conjunctivitis repeated in the period
of pollen season. Both Fce RI-binding and total IgE were
significantly greater in AKC than in SAC patients;
however, the proportion of Fce RI-binding IgE was signifi-
cantly higher in SAC than in AKC patients (Table 1). There
appears to be two subgroups of the AKC patients, based
on the proportion of Fce RI-binding IgE. One group of 11
patients has more than 40% of Fce RI-binding IgE and the
other has less than 40%. However, there is no significant
difference in the severity of corneal complications or in
the incidence of cataract and retinal detachment between
these two groups. These results may reflect the difference
of allergic states in these diseases, namely chronic and
acute allergic states. In a chronic allergic state, such as
AKC, the absolute quantities of Fce RI-binding and total
IgE were increased, but the proportion of Fce RI-binding
IgE was decreased. This suggests that in hyper-IgE sera
there may be some serum factors that interfere with IgE
binding to Fce RI18–26 and/or IgE that is structurally unable
to be bound, due to carbohydrate modification and/or
crucial changes of the primary sequence in the Fce chain.
Whatever these factors may be, our results indicate that
the proportion of Fce RI-binding IgE is higher in acute
allergic diseases, such as SAC, and the evaluation of
Fce RI-binding IgE fraction may contribute to a distinction
between IgE-dependent acute allergic diseases and
chronic allergic diseases.
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